The confirmed results from Phase II clinical trials reveal that antibodies against PD-L1 (durvalumab or pembrolizumab) in combination with PARPis (olaparib or niraparib) exhibit a good response against germline BRCA1/2-mutated breast cancer and other cancers (124). This evidence concerns the gene BRCA1 and breast cancer.